Ardea Biosciences — Corporate Update (November 2007)
34 slides from Ardea Biosciences's corporate update, Nov 28, 2007
Slide 1: Company Update November, 2007
Company Update November, 2007
Slide 2: Safe Harbor Statement
Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially
Slide 3: Background
5 Acquired R&D programs from Valeant in December 2006 Assembled new, seasoned management team Rich pipeline of small-molecules focused on viral diseases, cancer and inflammation Fully equipped laboratories and integrated R&D organization Background
Slide 4: Investment Highlights
7 By YE07, four NCEs in man in three indications, with additional indications in inflammatory diseases in 1H08 Positioned to achieve clinical POC quickly and cost- effectively in disease areas of focus Targeting multi-billion-dollar markets Potential for significant enhancements over standard of car
Slide 5: Ardea's Clinical-Stage Pipeline
9 RDEA119 2nd NNRTI RDEA119 2nd MEKI RDEA806 RDEA806 Initiate Phase 1 4Q07 Initiate FIH 4Q07 Initiate FIH 4Q07 Initiate Phase 2a 4Q07 Cancer/Inflammation Initiate Clinical Trial 1H08 Initiate Phase 2 1H08 NNRTI for HIV HIV Gout MEKI for Cancer MEKI for Inflammation Discovery Preclinical Phase 0/1 Ph
Slide 6: HIV Market Opportunity
11 Over $8 billion mature market focused on safety and convenience Three primary classes of therapies: 10 approved protease inhibitors (PIs) 11 nucleosides (NRTIs; single agents and combinations) Only 3 approved non-nucleosides (NNRTIs) One not actively promoted Efavirenz (Sustiva(r), Bristol-Myers
Slide 7: NNRTI Target Product Profile
13 Highly active against efavirenz-resistant strains High genetic barrier to resistance Improved safety profile Reduced CNS toxicity Improved lipid profile Easy-to-formulate combination pill Long half-life Once daily for first-line Once or twice daily for second-line Used in combination with current
Slide 8: RDEA806 Antiviral Activity
15 Virus Prevalence* RDEA806 RDEA806 Efavirenz Efavirenz Virus Prevalence* EC50 (nM) FC** EC50 (nM) FC** wt 3.0 0.4 K103N 88.5% 2.3 0.76 5.9 16 K103N-P225H 32.7% 10.3 3.4 77.9 212 K103N-V108I 28.8% 2.0 0.67 15.3 42 K103N-K101Q 16.3% 11.6 3.8 21.8 60 K103N-L100I 10.6% 1.6 0.53 636 1732 G190S 10.6% 3.
Slide 9: Head-to-Head Comparison of NNRTIs
17 EC50 (nM) EC50 (nM) EC90 (nM) EC90 (nM) w/o HS 40% HS w/o HS 40% HS RDEA806 4.7 27.4 (15 ng/ml) 13.5 110 (61ng/ml) TMC-125 0.9 10.5 3.8 110 TMC-278 0.9 12.3 2.2 56.2 Efavirenz 0.6 8.0 1.6 42.2 RDEA806 has greater binding to fetal bovine serum in culture media. Therefore, while values for RDEA806
Slide 10: Phase 1 SAD and MAD Studies
19 SAD (n = 74) Single ascending doses from 50 mg to 600 mg Food effect Impact of ritonavir on RDEA806 Evaluation of two formulations MAD (n = 24) 300 mg bid 500 mg bid 400 mg MR bid 19 SAD = Single-ascending dose MAD = Multiple-ascending dose BID = Twice daily MR = Modified-release capsules Present
Slide 11: Mean Trough Concentrations of RDEA806
Conc. (µg/mL) EC50 = 15 ng/mL EC90 = 61 ng/mL Day 0.01 0.10 1.00 2 4 6 8 10 12 14 300 mg bid 400 mg MR bid 500 mg bid 21 EC50 = concentration required to kill 50% of virus in vitro; values adjusted for protein binding EC90 = concentration required to kill 90% of virus in vitro; values adjusted for p
Slide 12: Mean Concentration-Time Profiles of RDEA806
Time (hr) 0.001 0.010 0.100 1.000 0 10 20 30 40 50 60 70 80 RDEA806 500 mg day 14 EC50 = 15 ng/mL T1/2 12.9 hr T1/2 = 9.9 hr Terminal half-life = 10-13 hr, providing coverage for missed doses 23 Mean Concentration-Time Profiles of RDEA806 Following 300 mg or 500 mg BID Dosing
Slide 13: Adverse Events in RDEA806 MAD Study
25 Preferred Term Placebo (N=6) 300 mg bid (N=6) 500 mg bid (N=6) 400 mg MR bid* (N=6) Total RDEA806 (N=18) Number with AEs 3 4 5 5 14 Number of AEs 7 9 10 7 26 Abdominal pain 1 (17%) 2 1 3 (17%) Constipation 2 1 3 (17%) Diarrhea 1 (17%) 2 2 (11%) Dizziness 1 (17%) 1 1 (6%) Fatigue 1 (17%) 1 1 (6%)
Slide 14: Change in Cholesterol in MAD Study
* Efavirenz data adapted from initial 21 days of TMC278-C204 27 MAD results consistent with 13% decrease in cholesterol observed in 28- day monkey study Change in Cholesterol in MAD Study
Slide 15: Change in Triglycerides in MAD Study
29 *Efavirenz data adapted from initial 21 days of TMC278-C204 Triglycerides were not measured in the 300 mg bid cohort Change in Triglycerides in MAD Study
Slide 16: Conclusions
31 RDEA806 was generally safe and well tolerated at all dose levels No grade 3 or 4 adverse events reported No CNS toxicity Total cholesterol and triglycerides trended down AUC increased linearly with dose* Terminal half-life at highest doses was 11-13 hr Much higher barrier to genetic resistance* N
Slide 17: New Indication for RDEA806
33 We discovered a new indication through serendipity 33 RDEA806 produced exposure- dependent decreases in uric acid in the MAD study New Indication for RDEA806
Slide 18: Reduction in Serum Uric Acid in RDEA806 MAD Study
35 35 * * * * * * *p < 0.001 Mean SUA Level (mg/dL) Mean SUA Level (mg/dL) Mean SUA Level (mg/dL) Mean SUA Level (mg/dL) Mean SUA Level (mg/dL) Baseline Day 3 Day 10/14 [1] Change P Value [2] Placebo 5.66 6.12 5.78 3.0% 300mg bid 6.19 4.50 4.15 -31.6% < 0.001 500mg bid 4.94 2.94 3.06 -38.1% < 0.001
Slide 19: Reduction in Serum Uric Acid Increases with Higher Baselines
37 Baseline Serum Uric Acid (mg/dL) Reduction in Serum Uric Acid Increases with Higher Baselines
Slide 20: Why Lowering Uric Acid Is Important
39 * TAP Pharmaceuticals' febuxostat and Savient Pharmaceuticals' Puricase Gout: a painful and debilitating disease Inflammation Disfiguring nodules (tophi) Attacks of severe pain (flares) Kidney damage (nephropathy) Affects 3-5 million people in the U.S. Most common form of inflammatory arthritis i
Slide 21: Why There Is a Need for New Drugs
41 95% of treated patients receive allopurinol, but: Only 21% of patients achieved target reduction in uric acid with a standard dose in a controlled study1 Serious adverse events in 8%1 Rash in ~2%1,2 Major allopurinol hypersensitivity syndrome is rare, but has ~25% mortality2 1N Engl J Med 2005; 3
Slide 22: Development Strategy
43 Biologic activity and safety already demonstrated in 2-week healthy volunteer study 1H08: Initiate Phase 2 dose-ranging study with RDEA806 in patients with hyperuricemia and a history of gout We will also monitor triglycerides and cholesterol Currently investigating active moiety and mechanism of
Slide 23: Hyperuricemia in HIV
45 High rates of hyperuricemia in HIV patients 41% in the "HAART era" HIV protease inhibitors are associated with hyperuricemia Nephron Physiol 2006;103:p131-p138 Reducing uric acid levels in HIV patients may be beneficial Hyperuricemia in HIV
Slide 24: MEK as Anticancer Target
47 Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2) PD0325901 (Ph 2?) XL518 (Ph 1) RDEA119 (Ph 1) RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 47 MEK as Anticancer Target
Slide 25: RDEA119 is a Potent, Highly Specific MEKI
49 % Inhibition 1 6 11 16 21 26 31 0 20 40 60 80 100 1 6 11 16 21 26 31 MEK1 & MEK2 MEK1 & MEK2 0 20 40 60 80 100 Ron SRC RDEA119 PD-325901 (Pfizer) >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** MEK1/2 Enzyme IC50 17-50 nM Cellular pERK EC50 2.5-8.7 nM* *Cell lines: Colo205, A375,
Slide 26: Colo205 Human Colon Cancer Xenograft
51 51 0 10 20 30 40 Days Tumor volume (mm3) Vehicle RDEA119 25mg/kg RDEA119 50mg/kg RDEA119 100mg/kg Dosing Period 0 200 400 600 800 1000 1200 Lowest dose tested, 25 mg/kg, produced 7 PRs and 2 CRs out of 9 mice; 2 were tumor-free at end of study Colo205 Human Colon Cancer Xenograft
Slide 27: Brain/Plasma Ratio in Rat
53 5 mg/kg in rat ^ 48 mg/subject in human PD325901 = MEK inhibitor from Pfizer RDEA119 has less potential for CNS toxicity 53 Brain/Plasma Ratio in Rat
Slide 28: Phase 1 RDEA119-201 Study in Advanced Cancer Patients
55 55 Study 1^ End Point Safety, tolerability, PK 2^ End Points Pharmacodynamic (PD) measures: pERK, Ki67, Nras, Kras and Braf mutations; Antitumor activity by CT scan Location Von Hoff (Arizona), Weekes (UCHSC) Study Population Advanced cancer patients, all-comers until DLT reached, then expanded g
Slide 29: Inhibition of Cytokines and Preclinical Results
57 57 Significant activity with RDEA119 observed in: Rat carrageenan paw edema model Rat adjuvant-induced arthritis model MDS Pharma rat IBD model TNBS-induced mouse colitis model RDEA436 is from a different structural class than RDEA119 * PHA-induced cytokines in human PBMCs ** Linked to Crohn's di
Slide 30: Activity of RDEA119 in TNBS-induced Colitis in BALB/c Mice
59 RDEA119 administered orally for 5 days significantly reduced colonic damage 59 Naive Vehicle 150 mg/kg Sulfasalazine 3 mg/kg RDEA119 10 mg/kg RDEA119 Macroscopic Damage Score * p < 0.01 **p < 0.001 vs. vehicle (n=10/group) Damage Score (Mean +- SEM) Activity of RDEA119 in TNBS-induced Colitis in
Slide 31: Efficacy of RDEA436 in Carrageenan Paw Edema Model
Compounds dosed orally, 2 hr prior to carrageenan N = 6 male SD rats/treatment group *p < 0.01 Dunnett's test compared to vehicle 0% 40 % 55% 66% 63 % 38 % RDEA436 has superior efficacy to maximally effective dose of indomethacin 61 Efficacy of RDEA436 in Carrageenan Paw Edema Model
Slide 32: Financial Position
63 Summary Statement of Operations (In thousands, except per share data) Nine Months Ended Sept. 30, 2007 Revenue Operating expenses Interest and other income $2,827 $20,756 $1,876 NET LOSS $(16,233) NET LOSS PER SHARE $(1.67) 11.8 million common- equivalent shares outstanding Expect to end 2007 wit
Slide 33: Near-Term Anticipated Milestones
65 65 Date Drug Candidate Indication Event 4Q07 RDEA119 Cancer Phase 1 start 4Q07 RDEA806 HIV Phase 2a start 4Q07 NNRTI Follow-on HIV FIH micro-dosing 4Q07 MEKI Follow-on Cancer/ Inflammation FIH micro-dosing 1Q08 RDEA806 HIV Phase 2a results 2Q08 RDEA806 HIV Phase 2b start 1H08 RDEA806 Gout Phase 2
Slide 34: Ardea Biosciences
7, Wn- . Ardea) Biosciences ) Designing Solutions for Serious Diseases NASDAQ: RDEA